Get Started

Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference

Expects profitability for the 2021 fourth quarter and full year
Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion SystemTM

BOCA RATON, Fla. (January 5, 2022) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it expects record sales for the fourth quarter of 2021, resulting in over $25 million in sales for the year, and positive EBITDA and net income for both the fourth quarter and full year. Fourth quarter sales include the shipment of three SRT Systems to China. Based upon expectations for shipments during the current quarter, the company also expects to be profitable for the first quarter of 2022. Sensus expects to report 2021 financial results and hold an investment community conference call in February.

“I am very proud of our sales performance during 2021, and especially during the fourth quarter as our hard work to position the company to recover from the Covid-19 pandemic contributed to our success,” said Joe Sardano, chairman and CEO of Sensus Healthcare. “I congratulate everyone at Sensus Healthcare and note that our exceptional team performed well above expectations as we look forward to another profitable quarter to kick off 2022.”

Sensus also announces that its TransDermal Infusion SystemTM non-invasive drug delivery system for cosmetic and other dermatology applications will be featured at the 2022 Winter Clinical Dermatology Conference - Hawaii®. Mark S. Nestor, M.D., Ph.D., Director of the Center for Clinical and Cosmetic ResearchTM and the Center for Cosmetic Enhancement® in Aventura, Florida, and current President of the American Cutaneous Oncology Society, will discuss the system on Saturday, January 15th at 2:30 p.m. local time during a session titled “Integrating Aesthetics into Your Dermatology Practice.”

Mr. Sardano added, “We are excited that our TransDermal Infusion System will be highlighted by Dr. Nestor at the Winter Dermatology Clinical. Gaining visibility at this important conference helps broaden awareness and build support for our patient-friendly, needle-free method of delivering aesthetic medicines. It has been only one month since we began our exclusive U.S. distribution of this FDA-cleared product and we are encouraged by physician interest in its ability to deliver drugs that are otherwise not able to be absorbed, including Botox®, hyaluronic acid, lidocaine, collagen and others typically used in aesthetic procedures.”

Dr. Nestor will present the TransDermal Infusion System to more than 400 registered attendees at the Grand Hyatt in Kauai, and will discuss the patient benefits of incorporating the system into dermatology practices. He recently presented data at the 2021 Fall Clinical Dermatology Conference showing a more than 80% reduction in sweat 30 days after a single topical infusion of 50 units of onabotulinum toxin in the axilla, and has previously noted that studies have shown significant cosmetic improvement with topically applied hyaluronic acid filler using Sensus’ TransDermal Infusion System.

About the Winter Clinical

The annual Winter Clinical Dermatology Conference® is a four-day accredited CME course that provides a comprehensive update on the diagnosis and treatment of a variety of conditions related to medical, surgical and cosmetic dermatology.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The SculpturaTM modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam SculptingTM to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non- melanoma skin cancers and keloids with its SRT-100TM, SRT-100+TM and SRT-100 VisionTM systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from our international operations; legislation, regulation, or other governmental action , that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the

Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

In addition, even if future events, developments, and circumstances are consistent with the forward- looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Cautionary Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.


LHA Investor Relations

Kim Sutton Golodetz


[email protected]

Join Sensus Healthcare at the AAD Annual Meeting at the Boston Convention & Exhibition Center! We will be located in booth #4063.

Registration is Now Open. Register Here Today!

& Exhibition Center!

Life Science Leaders Unite To Advance the Industry in Florida


WEST PALM BEACH, Fla., Aug. 11, 2021 /PRNewswire/ -- BioFlorida has announced five new board members who will support the organization's effort to grow the life sciences industry in Florida.

"The life sciences industry in Florida is vibrant, and we're excited to welcome Thomas Equels of AIM ImmunoTech, Mark Friedman, PhD of Axogen, Geoff Green of Longeveron, Adam Grossman of ADMA Biologics, and Joe Sardano of Sensus Healthcare," said Nancy Bryan, President and CEO of BioFlorida. "Our new board members are leaders in their fields with a passion to unite with our diverse Board of Directors representing the various sectors and regions in Florida with a collective goal to advance the impressive, diverse life sciences ecosystem."

Today, the life sciences industry in the state represents 6,700 establishments and research organizations in biopharmaceuticals, medical technology, healthIT and bioagriculture that collectively employ nearly 94,000 Floridians.

"BioFlorida provides Florida's life sciences industry with a venue to collaborate to address global health challenges," said Rob Herzog, Chair of the BioFlorida Board and Vice President of Research and Operations at AdventHealth. "I look forward to working with our new board members to continue to build Florida as a life sciences destination."

The new board members began their two-year term on January 1, 2021. The five new board members are:

Thomas K. Equels, CEO, AIM ImmunoTech (Ocala): Mr. Equels has served as the CEO of AIM ImmunoTech since February 2016, after serving as President since 2015. Mr. Equels' successful legal career included extensive experience in the pharmaceutical sector. He also has served as a court-appointed receiver turning around businesses in several different fields. Mr. Equels received his JD with high honors from Florida State University. He is a summa cum laude graduate with a BS and an MS from Troy University. Mr. Equels is also a highly decorated combat aviator, twice awarded the Distinguished Flying Cross, awarded the Purple Heart, the Bronze Star and 15 Air Medals, including three for extraordinary valor. In 2012, he was knighted by Pope Benedict as a knight of the Papal States. Mr. Equels received the BioFlorida Weaver H. Gaines Entrepreneur of the Year for 2020.

Mark L. Friedman, PhD, Vice President of Regulatory Affairs & Policy, Axogen, Inc. (Alachua): Dr. Friedman joined Axogen in September 2006, and has served as Vice President of Regulatory Affairs and Quality Assurance for Axogen since November 2011 and Axogen Corporation since June 2011, and previously served as Director of Quality Assurance and Regulatory Affairs from for Axogen Corporation. Prior to joining Axogen, Dr. Friedman held several regulatory and quality leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance and Vice President of Quality and Regulatory. Dr. Friedman also worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory and as Vice President of Operations. AtriCure acquired Enable Medical in 2005. Dr. Friedman has over 30 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with startup medical product firms. Dr. Friedman has a PhD in Chemistry specializing in protein biochemistry from the University of Cincinnati.

Geoff Green, CEO, Longeveron, Inc. (Miami): Mr. Green has been with Longeveron (NASDAQ: LGVN) since 2016, and is a veteran of the life sciences and drug development industry. A versatile executive with a career spanning 25 years in both public and private companies, Mr. Green has held a variety of leadership roles throughout his time in the industry. Prior to joining Longeveron, he was VP of Operations at Partikula; VP, Business Development & Clinical Affairs at Accu-Break Pharmaceuticals; President and Acting CEO of DOR BioPharma [now Soligenix (NASDAQ: SNGX)]; VP of Business Development & Operations at Heart Genomics; and Director of Clinical Affairs at Innovative Drug Delivery Systems. Early in his career he spent several years managing oncology clinical trials at Memorial Sloan-Kettering Cancer Center, and as a research associate at Paramount Capital, where Mr. Green managed clinical trials for several portfolio companies. Mr. Green received a BA in biology from Kenyon College, and an MBA from Barry University's Andreas School of Business.

Adam S. Grossman, President & CEO, ADMA Biologics (Boca Raton): Mr. Grossman is a leader in the biopharmaceutical industry and has been the driving force behind ADMA Biologics' mission since its inception to develop and bring to market novel plasma derived products to address certain unmet medical needs for immune compromised patients. Mr. Grossman has over 25 years of experience in the blood and plasma products industry, which includes experience in launching new products, building and managing national and international sales forces, managing, and designing clinical trials as well as developing strategies and executing solutions to resolve complex quality assurance, biologics and pharmaceutical manufacturing and regulatory affairs issues. Additionally, he has negotiated and completed multiple business development and merger and acquisition transactions. Mr. Grossman is a member of the Plasma Protein Therapeutics Association North American Board and has been a member of the ADMA Biologics Board of Directors since 2007, has served as its President and CEO since October 2011, and was the President and COO between 2007 and October 2011. Mr. Grossman is a graduate of American University, receiving a BS in Business Administration, with a specialization in International Business and Marketing.

Joe Sardano, CEO, Chairman & Founder, Sensus Healthcare (Boca Raton): With over 35 years of management experience with such companies as CTI Molecular Imaging, GE Healthcare, Siemens Medical Systems, Elscint Inc., and Toshiba America Medical Systems, Mr. Sardano is a respected and recognized leader in the healthcare industry. He has been responsible for introducing and commercializing many new technologies and services, including PET and PET/CT, SPECT, MRI, Lithotripsy, Digital Radiography and Electronic Brachytherapy. Mr. Sardano established and led national and international sales and marketing organizations demonstrating consistent overachievement while driving customer centricity and market share. He has led several M&A initiatives from both the "seller" and "buyer" sides while establishing the processes for the integration of multi-faceted organizations and establishing their structures and "go to market" strategies. He currently is the President/CEO of Sensus Healthcare, a Medical Device company addressing the therapeutic treatments of NMSC and Keloid scars. He has been involved with many philanthropic organizations raising millions of dollars for Heart and Cancer research. Joe is originally from Montreal Canada where he graduated from Concordia University. He also attended McGill University, School of Management.

"Our new BioFlorida board members bring invaluable expertise to BioFlorida's mission of progressing product and technological innovation that improves the lives and health of Floridians," said Rob Finizio, Vice Chair of the BioFlorida Board and CEO, Co-Founder and Director of TherapeuticsMD. "I look forward to how BioFlorida's board relationships expand employment in Florida's life science industry and overall nourish the economic interests of the state. I'm also looking forward to working closely with Rob Herzog as I make the transition to Board Chair of the BioFlorida Board of Directors in January 2022."

The new BioFlorida board members join 31 current board members including: Mario Carranza (Nemours Children's Health System), David Day (DDay Ventures), Rob Herzog (AdventHealth), Emily Gresham (Florida International University), Norma Sue Kenyon (University of Miami), Valerie McDevitt (AdventHealth), Karen Moore (Moore), Adam Hunter (Cherry Bekaert), Jim O'Connell (University of Florida), Jarett Rieger (Moffitt Cancer Center & Research Institute), Raquel Rodriguez (Buchanan Ingersoll & Rooney PC), Svetlana Shtrom (University of Central Florida), David Smith (Akron Biotech), Holly Bates Snow (Amgen), Mark Strong (LifeLink), Sue Washer (AGTC), Julie Watson Lampley (Epstein Becker & Green, P.C.), David Conrad (University of South Florida), Charles Bruce (Mayo Clinic), Nancy Bryan (BioFlorida), Douglas Calder (Vycellix), Les Croland (Legal Counsel), Brian Dorn (Arthrex), Antonio J. Ferreira (Johnson & Johnson), Robert Finizio (TherapeuticsMD), Glenn Ladwig (Saliwanchik, Lloyd & Eisenschenk), Gregory Nelson (Fox Rothschild), Michael Paredes (Genentech), Steve Parkinson (Lakewood-Amedex), Juan Toro (Medtronic), and Juan Carlos Varela (Globant).

About BioFlorida

BioFlorida is the voice of Florida's life science industry, representing 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors that collectively employ 94,000 Floridians. BioFlorida's member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state.


Contact: Courtney Cox, PR Counsel BioFlorida

(850) 224-0174 or [email protected]

To our valued customers,
  We wanted to share this editorial entitled, "COVID-19: Spirliang of Frailty in Older Italian Patients" written by A.M. Abbatecola and R. Antonelli-Incalzi. In this article it is highlighted that "due to the rapid spread of the coronavirus in Italy, there seems to be a deadly trend toward mortality with COVID-19 in older patients with specific comorbidities, thus identifying a new “COVID Spiraling Frailty Syndrome”." Available data from the ISS show that the most common commorbidities observed in all Italians dying with COVID-19 are "arterial hypertension (74.7%) and Type 2 Diabetes (30.5%)". Please read the full article to learn more. We can all get through this together!

Skin cancer can be broadly split in to two types: melanoma and non-melanoma. The most common non-melanomas include basal cell carcinoma and squamous cell carcinoma, for which the main treatment is surgery. However, other non-surgical options are emerging, including superficial radiation therapy (SRT), a unique type of photon radiotherapy.

To learn more about SRT we recently spoke with Joe Sardano, CEO at Sensus Healthcare. Joe explains what SRT is, how it works, and the cancers it is particularly suited to treating.

Read the full article here.

As a part of my series about “The Future of Healthcare” I had the pleasure of interviewing Joseph C. Sardano, Chief Executive Officer, Sensus Healthcare Inc. A recognized leader in the healthcare industry, Joe Sardano has spent more than 30 years in management and marketing. He has a successful history of introducing and commercializing new technologies and services in many areas, including electronic brachytherapy, PET and PET/CT, SPECT, MRI, lithotripsy and digital radiography. Before joining Sensus Healthcare, Sardano held leadership and management roles at CTI Molecular Imaging, GE Medical Systems, Siemens Medical Systems, Elscint Inc and Toshiba America Medical Systems, among others.

Read the full article here.

Researchers found in a retrospective study of 297 surgically excised keloids with superficial radiation therapy around the excision site that only 3% recurred during an average 6-month follow-up.

Read the full article here.

Dr. Kenrick Spence, a Central Florida doctor, discusses the benefits of the SRT-100+ for keloid removal at Hilcrest Plastic Surgery in Orlando. With over 18 million people suffering from keloids, the market to remove the painful and itchy overgrowths of scars is highly in demand in this community.

Read the full article here.

Dr. Kristine A. Romine, MD, CEO and Founder of Camelback Dermatology & Skin Surgery in Phoenix, AZ, explains the difference the personalized approach to skin cancer treatment that SRT provides to skin cancer patients.

Read the full article here.

Superficial Radiation Therapy and our CEO, Joe Sardano, are making headlines with Dermatology Times. This article highlights the benefits of using SRT alongside Mohs surgery when treating skin cancer patients. With 80 percent of skin cancers appearing on the face and neck, a less invasive approach is very sought out by sufferers.

Read the full article here.

Different Skin Cancer TreatmentsIt is crucial for dermatologists to be at the frontline of the skin cancer epidemic. Jeffrey S. Fromowitz, MD, FAAD, understands the difficulty educating patients and providing physicians with the different skin cancer treatments that currently are available. Surgery is typically coupled with downtime and invasive procedures. Since many skin cancer treatment recipients are seniors, the invasive route is often not an option. Dr. Fromowitz explains the pros and cons of the different skin cancer treatments in this article.

Over the past several years, Mr. Sardano, CEO of Sensus Healthcare, has worked tirelessly to offer a non-surgical solution for non-melanoma skin cancer and an effective treatment for keloid scars. The state-of-the-art Superficial Radiation Therapy (SRT) technology is the non-surgical treatment option dermatologists and oncologists have been waiting for.

Upon receiving the "Non-Physician Non-Surgical Innovator of the Year" award at the 2018 Aesthetic Awards, Mr. Sardano remarked, “We are absolutely thrilled, surprised and excited to be recognized. We take the award seriously. We will work hard to live up to the expectations that have been set, and continue to provide world-class technology that works well within the physician’s environment.”

Read the full article here.
Dr. Ellen Turner discusses with CEO Money host, Michael Yorba, the non-invasive and pain free benefits of treating skin cancer with Superficial Radiation Therapy. With Dr. Turner's two dermatology practice locations in the Dallas area, she knows that one in three Texans will develop skin cancer in their lifetime. Check out the video below or read the full article here.


Inc. recently sat down with 19 successful founders and executives to discuss how they push themselves to the next level. When asked about his support system, CEO of Sensus Healthcare, Joe Sardano, said, "One maxim our team hangs onto is, 'Who packs your parachute?' This saying comes from an old story originated by a U.S. Navy pilot. Everyone relies on someone else to provide what they need to get through the day. Throughout life's daily challenges, it's important to remember who packed your parachute. In short, remember and appreciate the people who, at times, hold your fate in their hands. I'm lucky to have an excellent team that supports and lifts up our entire community, making sure we provide a safe and soft landing across all levels of our business, for our patients, physicians and salespeople."
Read the full article here.
CEO, Chairman and Co-Founder of Sensus Healthcare, Joe Sardano, was recently interviewed for a feature in AAWC's research journal, Ostomy Wound Management (OWM).
Read the full interview here.
BOCA RATON, Fla.July 31, 2018,/PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), today announced that the Company's CEO, Joe Sardano, has been named non-physician, nonsurgical "Innovator of the Year" at the 2018 Aesthetic Awards, hosted by The Aesthetic Channel, a media resource for cosmetic doctors. Sensus Healthcare was also named a runner-up for "Company Nonsurgical Innovator of the Year."
Read the full press release here.

Dr. Kevin Schewe the Radiation Oncologist and Medical Director at Alliance Cancer Care at Red Rocks discusses the dangers of UV rays, the different types of skin cancer and SRT with Colorado's Best on FOX network Channel 2 and Channel 31 in Denver.

Watch the video here.

Lisa Pace has had 86 skin cancer surgeries and she's only 42 years old. She was in her 20s when she discovered she had skin cancer after years of using tanning beds. In her interview with People Magazine, she discusses the importance of sun-protection and the dangers of tanning beds. She adds: “I want people to realize that it can happen to anybody. I’m adamant about young people knowing this before it’s too late.”

Read the full article here.

In this week's CEO Money segment Michael Yorba sits down with Dallas dermatologist, Dr. Ellen Turner to learn about skin cancer, and why her practice is using Superficial Radiation Therapy (SRT) — a new, non-surgical skin cancer treatment option that has a remarkable cure rate.

Read the full article and listen to the interview here.

City & Shore Magazine recently wrote an article regarding the alternative treatment options to skin cancer surgery. Dr. Jason Green, DO and SRT was featured in the article. Check out the full article here.

Start your journey to a happy & healthy recovery.
Or search for a treatment location:
Begin Search
©Copyright 2022 - Sensus Healthcare - All Rights Reserved.